Active	Status	Sponsor type	Region	Phase	Filter
9 Active 4 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl) / Sanofi
NCT06752850: A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis	Recruiting	4	35	Europe	Efanesoctocog alfa	Swedish Orphan Biovitrum, PSI CRO	Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia, Classic Hemophilia, Synovial Hypertrophy	12/26	12/26
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa	Not yet recruiting	3	78	Europe	Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)	Swedish Orphan Biovitrum, PSI CRO	Severe Haemophilia A	08/26	08/26
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa	Active, not recruiting	3	93	Europe, RoW	Efanesoctocog alfa, BIVV001	Swedish Orphan Biovitrum, Syneos Health	Hemophilia A, Severe	05/26	05/26
XTEND-ed, NCT04644575 / 2020-002215-22: Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A	Active, not recruiting	3	261	Europe, Canada, Japan, US, RoW	efanesoctocog alfa (BIVV001)	Bioverativ, a Sanofi company	Hemophilia A	01/27	01/27
NCT04770935: To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)	Completed	1	6	Europe, US	efanesoctocog alfa (BIVV001)	Bioverativ, a Sanofi company	Von Willebrand's Disease (VWD)	12/22	12/22
NCT06579144: Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A	Not yet recruiting	1	24	Europe	Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio	Swedish Orphan Biovitrum, PSI CRO	Hemophilia A	03/25	04/25
ACTIVIIITY, NCT06530030: Goal Attainment and Physical Activity in People With Hemophilia A	Not yet recruiting	N/A	35	NA	efanesoctocog alfa, Altuviiio	Sanofi	Hemophilia A	04/26	07/26
PROTECT-ALT, NCT06684314: A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan	Recruiting	N/A	120	RoW	Efanesoctocog alfa, ALTUVIIIO, BIVV001	Sanofi	Hemophilia A	08/31	08/31
NCT05911763: A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A	Recruiting	N/A	200	US	Efanesoctocog Alfa BIVV001, ALTUVIIIO	Sanofi	Hemophilia A	06/28	06/28